Our leading subject matter experts share their insightful analysis and points of view to help you stay abreast of industry trends
Cell and gene therapies are no longer reserved only for ultra-rare diseases. In many therapeutic areas (TAs), advances in viral vector delivery, gene editing technologies, and cell-based medicine are enabling…
In many therapeutic areas, especially oncology, physicians have been using early screening tests for decades. Designed to identify the early signs of a disease or condition before any noticeable symptoms…
Biomarker testing is a cornerstone of modern oncology, transforming how clinicians diagnose, stratify, and treat cancer. By identifying particular genetic, molecular, or protein characteristics in a patient’s tumor or blood…
To better understand what 2026 might bring, we asked three MMIT market access experts to share their perspectives on upcoming market shifts. Read on for key insights into the year…
Transthyretin amyloidosis (ATTR) has rapidly shifted from a rarely recognized, fatal condition into one of the most closely watched rare-disease markets in biopharma.
With multiple therapeutic entrants, distinct scientific platforms,…
The oncology market is growing rapidly, driven by advancements in diagnostic technology, new biomarker testing, and a wealth of targeted therapies. The non-small cell lung cancer (NSCLC) space is especially…
As medicine evolves, even smaller therapeutic areas are impacted by scientific breakthroughs and novel technologies, leading to an eruption of new therapies. Hereditary angioedema (HAE), a rare genetic disorder affecting…
As high-cost specialty treatments become more common, manufacturers are turning to innovative contracting to boost coverage for their products. Many cell and gene therapies, orphan drugs, and oncology therapies are…
This article was originally published in BioPharma Dive.
Pharma companies are increasingly turning to real-world data to answer their commercial business questions, but not all realize that unstructured EMR data…
In a recent post on specialty carve-out mechanisms, we examined how payers’ use of specialty benefit managers and alternative funding programs can impact manufacturers’ patient assistance programs (PAPs). Today’s post…
